46 results about "Enzyme Inhibitor Drugs" patented technology

A medical prosthetic device or medical implant containing a metal material (A) selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy, wherein surface parts of the metal material (A) are coated with a layer of a corresponding hydride material (B) selected from titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium and/or vanadium hydride, respectively, said device or implant being characterised in that the layer of hydride material (B) comprises one or more biomolecule substances (C) associated therewith. The device or implant exhibits improved biocompatibility. The metal material (A) is preferably titanium. The biomolecule substance (C) may be selected from the following types of substances: Natural or recombinant bio-adhesives; natural or recombinant cell attachment factors; natural, recombinant or synthetic biopolymers; natural or recombinant blood proteins; natural or recombinant enzymes; natural or recombinant extracellular matrix proteins; natural or synthetic extracellular matrix biomolecules; natural or recombinant growth factors and hormones; natural, recombinant or synthetic peptide hormones; natural, recombinant or synthetic deoxyribonucleic acids; natural, recombinant or synthetic ribonucleic acids; natural or recombinant receptors; enzyme inhibitors; drugs; biologically active anions and cations; vitamins; adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (A TP); marker biomolecules; amino acids; fatty acids; nucleotides (RNA and DNA bases); and sugars.

The invention provides a penicillazine derivative and the preparation method and the application thereof. The preparation method comprise the following steps: culturing strains of marine fungi in a culture medium, fermentation culturing the fungi in a fermentation culture medium, filtering the obtained fermented solution to remove thalli; heating to concentrate the filtrate and extracting with an organic solvent; carrying out the chromatographic separation and concentrating the eluate to obtain penicillazine; and adding an alkylation or acylation reagent and reacting to obtain the penicillazine derivative. The penicillazine derivative derived from the marine fungihas an enzyme inhibiting activity, can effectively inhibit Alpha-glucosidase, and can be applied for developing enzyme inhibiting pharmaceuticals. The raw material can be produced in a large scale, and the application prospect is wide.

The invention provides applications of four kaurane diterpene compounds in preparation of glycosidase inhibitor medicines. The four compounds capable of highly inhibiting alpha-glycosidase activity are natural compounds which are high in safety and capable of rapid natural degradation without residue in the environment. The four compounds are obtained by separation from wedelia trilobata, and other plant materials. The plant materials are rich in source. A preparation process is easy in operation. Monomers of the four compounds are stable and liable to store. The alpha-glucosidase inhibition activity of the four compounds is obviously higher than or equivalent to that of acarbose that is a clinic medicine. The four compounds are extremely likely developed into effective and safe alpha-glucosidase inhibitor medicines used for preventing and treating type II diabetes, and have good prospects.

The invention provides a preparation method of spermacoce latifolia triterpenoids and an application of the spermacoce latifolia triterpenoids in preparation of a glycosidase inhibitor medicine. Six compounds for intensively inhibiting the activity of alpha-glycosidase provided by the invention are natural compounds which are high in safety, and can be naturally degraded rapidly without a residue in the environment. The compounds can be separated from plant materials such as spermacoce latifolia; the plant materials are abundant in source; and the preparation process is easy to operate. Monomers of the six compounds are relatively stable and easy to store; the alpha-glycosidase inhibiting activity is obviously higher than that of clinical medicine acarbose; and the compounds are extremely likely to be further developed into the effective and safe alpha-glycosidase inhibitor medicines for preventing and treating type 2 diabetes mellitus, and have relatively good prospects.

The invention discloses a compound 2-hydroxyl-3-carbonyl-23-oleanolic acid-1,4,12-triene-28-acid as well as a preparation method and application of the compound preparation of a glycosidase inhibitor medicine. An alpha-glucosidase inhibitor with high efficiency is extracted and separated from an akebia plant, a plant material is rich in source, an extraction preparation method is easy to operate, the plant can be used for a long time without being damaged when extraction is performed by adopting a plant fruit, and thus the economic benefit can be increased, and the environment friendliness is achieved; the monomeric compound is stable and easy to store. Pharmacological experiments prove that the inhibitory activity of the compound 2-hydroxyl-3-carbonyl-23-oleanolic acid-1,4,12-triene-28-acid is stronger than that of a first-grade diabetes drug acarbose by about 16 times, and thus the compound 2-hydroxyl-3-carbonyl-23-oleanolic acid-1,4,12-triene-28-acid can be expected to be further developed into a medicine for clinically treating type 2 diabetes mellitus and is good in prospect.

The invention discloses new 2-hydroxy-3-carbonyl-23, 29-dinorolean-1, 4, 12, 20 (30)-tetraene-28-acid, a preparation method thereof and an application in preparation of glucosidase inhibitor medicines. An alpha-glucosidase inhibitor with strong effects is extracted and separated from an akebia plant, and plant sources are rich. Furthermore, when fruit extraction is performed, the plant can not be damaged and can be utilized for a long time, so that economic benefits are improved, and the environment-friendly effect is further achieved. Pharmacological experiments show that the in-vitro alpha-glucosidase inhibition activity of the compound, namely 2-hydroxy-3-carbonyl-23, 29-dinorolean-1, 4, 12, 20 (30)-tetraene-28-acid is about 5 times of that of a first-line diabetes medicine, namely acarbose, so that the compound is expected to be used for developing medicines for preventing and treating type II diabetes and has good application and development potentials.

The invention discloses a preparation method of Plk (Polo-like kinase) inhibitor drug intermediate 7-amino-2,3-dihydrobenzofuran-4-formic acid (I), which comprises the following steps: by using 3-hydroxy-4-nitrobenzoic acid as a starting material, firstly esterifying, then condensing the starting material with 2-halogeno acetaldehyde or 2-halogeno acetal under the effect of an alkali acid-binding agent to realize alkylation of hydroxyl, then performing Friedel-Crafts reaction under the catalysis of protonic acid or Lewis acid, performing cyclization to obtain 7-nitrobenzofuran-4-methyl formate, and finally performing catalytic and hydride reduction and hydrolysis to obtain high-yield 7-amino-2,3-dihydrobenzofuran-4-formic acid (I). According to the invention, the synthetic route is simplified and optimized, the reaction processes are reduced, the technology is simplified, the cost is lowered and the production yield is high, and the 7-amino-2,3-dihydrobenzofuran-4-formic acid can be produced in large scale to meet the usage requirements, and is suitable for industrial production.

The invention discloses novel 2,3-dihydroxyl-30-noroleanolic acid as well as a preparation method thereof and application thereof in preparing a glycosidase inhibitor medicament. According to the novel 2,3-dihydroxyl-30-noroleanolic acid as well as a preparation method thereof and application thereof disclosed by the invention, a strong-effect alpha-glucosidase inhibitor is extracted and separated from akebia plants, and the plants are rich in resource. Moreover, when fruit extraction is adopted, the plants are utilized for a long time without being damaged, so that not only can economic benefits be improved, but also environmental friendliness can be achieved. A pharmacological experiment shows that a compound 2,3- dihydroxyl-23-aldehyde group-nor olean-12,20(29)-diene-28-acid has in-vitro alpha-glucosidase-inhibitory activity stronger than that of a first-line diabetes medicament acarbose, is expected to be further developed into a medicament for preventing and treating type II diabetes mellitus, and has good application and development potentials.

The invention relates to an alkaloid compound, a method for preparing the alkaloid compound and an application of the alkaloid compound as enzyme inhibitor. During preparation, strain culture is first carried out to a marine fungus in a culture medium, and then fermentation culture is carried out to the fungus in a fermentation culture medium; obtained fermentation liquid is filtered to eliminate mycelium; filtrate is heated, concentrated and extracted through ethyl acetate; chromatographic separation is carried out, and after obtained eluent is concentrated, penicillazine is obtained; bromine or manganese dioxide is added to a solution dissolving the Penicillazine, and then Penicillazines 1 and 2 are respectively obtained after reaction; or acetic anhydride is added to a solution dissolving the Penicillazine 2, and then Penicillazines 3 and 4 are obtained after reaction. An alkaloid derivative derived from the marine fungus can effectively inhibit human topoisomerase I, can be used for developing enzyme inhibitor medicine, and has raw materials that can be produced in large scale.

The invention discloses a chromones compound, a preparing method thereof and chromones compound application in preparing antineoplastic and enzyme inhibitor medicines. The sulfur-containing chromones compound shown in a formula (I) is strong in effect of inhibiting the growth of lung adenocarcinoma cells or histocyte lymphoma cells or leukemia cells or gastric carcinoma cells or acute lymphoblastic leukemia cells or acute myeloblastic leukemia cells or hepatoma carcinoma cells. The chromones compound inhibits JAK3, AuroraA and ABL. The chromones compound has good application prospects in preparing the antineoplastic and the enzyme inhibitor medicines.

Compositions include highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly-concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

The invention discloses applications of a compound ent-kaur-16-en-19-oic acid in preparation of glycosidase inhibitor medicines. The compound ent-kaur-16-en-19-oic acid has high alpha-glucosidase inhibition activity, and the alpha-glucosidase inhibition activity of the compound is even higher than that of acarbose that is a first-line medicine for diabetes, and therefore the compound can be used for development and preparation of potential medicine candidates used for preventing and treating physiological changes or diseases caused by or related to alpha-glucosidase, wherein the physiological changes or diseases caused by or related to the alpha-glucosidase include but is not limited to type II diabetes.

The invention discloses a precursor compound of a novel abiraterone medicine as well as a preparation method and application thereof. The structure of the compound is shown as a formula I in the specification. The invention further provides a preparation method of the compound shown in the formula I, hydrochloride of the compound shown in the formula I, a preparation method of the compound and hydrochloride and application of the compound and hydrochloride in the preparation of CYP17 enzyme inhibitor drugs. The compound provided by the invention provides improved oral bio-availability and pharmacokinetic characteristics, can be used as a human body CYP17 enzyme inhibitor, and can be used for treating urogenital or androgen-related diseases, such as cancers or other androgen-related diseases, including prostatic cancer, breast cancer, prostatic hyperplasia and the like.

The invention discloses 23-norursane triterpene compound, its preparation method and its application in the preparation of glycosidase inhibitor drugs. The present invention separates and obtains the 23-norursane triterpene compound represented by the formula I with strong inhibitory activity of α-glucosidase from Akebia trifoliate, which has low potential toxic and side effects, rich source of plant materials, and when plant fruit is used for extraction It can also make the plant itself not too damaged and can be used for a long time, and the monomer compound is stable and easy to store, and its activity of inhibiting α-glucosidase is significantly stronger than that of clinical drug acarbose, which is likely to be further developed into an effective and safe The α-glucosidase inhibitor drugs for the prevention and treatment of type Ⅱ diabetes have good prospects.

The invention provides furocoumarin having DPPIV enzyme inhibition activity and a preparation method of the furocoumarin having DPPIV enzyme inhibition activity. The structural formula of a furocoumarin type compound 6-beta-D-glucosyl-6,7-dihydroxy-5-benzfuran methyl propionate is as shown in a formula (I), and the furocoumarin type compound is separated from dry products or fresh products of fruits, roots, stems, branches or leaves of clausena lansium. In vitro pharmacological experiment confirms the compound 6-beta-D-glucosyl-6,7-dihydroxy-5-benzfuran methyl propionate has significant inhibition effects on DPPIV enzymes, the IC50 value of the compound 6-beta-D-glucosyl-6,7-dihydroxy-5-benzfuran methyl propionate is 117+/-8.7[mu]M, which illustrates that the compound 6-beta-D-glucosyl-6,7-dihydroxy-5-benzfuran methyl propionate has favorable DPPIV enzyme inhibition activity. The furocoumarin type compound 6-beta-D-glucosyl-6,7-dihydroxy-5-benzfuran methyl propionate is hopeful to be used as a lead compound for developing a novel DPPIV enzyme inhibitor medicine.

A class of compounds having a pyrimidone structure as a chymase inhibitor drug, specifically discloses the compound represented by formula (I), its pharmaceutically acceptable salts and isomers thereof, and pharmaceutical compositions containing them .